Situation: A 45-year-old man with bulky diffuse large B-cell lymphoma is admitted for his first cycle of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. Thirty-six hours after chemotherapy, his results are: Potassium: 6.4 mEq/L (3.5–5.0) Phosphate: 6.9 mg/dL (2.5–4.5) Calcium: 7.9 mg/dL (8.5–10.5) Uric acid: 11.8 mg/dL (3.5–7.2) He has no numbness, tingling, or muscle twitching, and his urine output is 45 mL/h. Which result poses the MOST immediate threat to his life?

High potassium, phosphate, and uric acid with low calcium after chemotherapy for a bulky lymphoma is the pattern of tumor lysis syndrome. Of these, hyperkalemia can cause fatal dysrhythmias within minutes to hours, so it is the most immediate threat. His hypocalcemia causes no symptoms, and the high uric acid and phosphate threaten the kidneys more gradually while urine output is still adequate.

Clinical situation A 45-year-old man with bulky diffuse large B-cell lymphoma (DLBCL) is admitted for his first cycle of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). Thirty-six hours after chemotherapy, laboratory results show potassium 6.4 mEq/L, phosphate 6.9 mg/dL, calcium 7.9 mg/dL, and uric acid 11.8 mg/dL. He has no neuromuscular symptoms and urine output is 45 mL/h.

Core interpretation This combination of hyperkalemia, hyperphosphatemia, hyperuricemia, and hypocalcemia after cytotoxic chemotherapy for a bulky, high-grade lymphoma is the classic metabolic signature of tumor lysis syndrome (TLS). TLS occurs when massive tumor cell breakdown releases intracellular contents into the bloodstream faster than the body can clear them ^[1][2][3][4]. In bulky DLBCL, the large tumor burden and high proliferative rate make spontaneous or chemotherapy-induced cell lysis particularly dangerous within the first 24–72 hours after treatment begins.

Why potassium is the most immediate threat Among the four abnormalities, hyperkalemia carries the highest short-term mortality risk because elevated serum potassium directly destabilizes the resting membrane potential of cardiac myocytes. As extracellular potassium rises, the resting membrane potential becomes less negative, bringing cardiac cells closer to threshold. This initially increases excitability but then paradoxically depresses conduction, leading to peaked T waves, widened QRS complexes, and ultimately ventricular fibrillation, asystole, or sudden cardiac death within minutes to hours ^[1][2][3]. The patient’s potassium of 6.4 mEq/L is already above the threshold where fatal dysrhythmias become a realistic concern, even in the absence of current symptoms. The expert TLS panel consensus explicitly identifies hyperkalemia as a driver of cardiac arrhythmias and potentially sudden death ^[1]. Watch out! A patient with TLS-related hyperkalemia can appear hemodynamically stable one moment and arrest the next; the absence of ECG changes or symptoms does not reduce the urgency of treatment.

Why the other abnormalities are less immediately lethal Hyperphosphatemia and hyperuricemia primarily threaten the kidneys through intratubular precipitation of calcium phosphate and uric acid crystals, which can lead to acute kidney injury ^[3][4]. However, this process evolves over hours to days, and the patient’s urine output of 45 mL/h indicates that renal perfusion and tubular flow are still adequate at this point. Hypocalcemia in TLS is usually secondary to hyperphosphatemia—phosphate binds calcium and precipitates in tissues—and can cause neuromuscular irritability, tetany, seizures, or QT prolongation ^[1][4]. This patient has no numbness, tingling, or muscle twitching, so the hypocalcemia is currently asymptomatic and less immediately dangerous than the potassium level.

Abnormality	Primary danger	Time course	Why not the top priority here
Hyperkalemia (6.4 mEq/L)	Ventricular dysrhythmias, cardiac arrest	Minutes to hours	This is the most immediate threat
Hyperuricemia (11.8 mg/dL)	Uric acid crystal nephropathy, AKI	Hours to days	Urine output still adequate
Hyperphosphatemia (6.9 mg/dL)	Calcium phosphate precipitation, AKI	Hours to days	Renal injury is gradual
Hypocalcemia (7.9 mg/dL)	Tetany, seizures, QT prolongation	Variable	No neuromuscular symptoms present

Clinical reasoning for the licensure exam When a question presents multiple simultaneous electrolyte derangements after chemotherapy, the correct answer is almost always the one that can kill the patient fastest. Hyperkalemia is the only abnormality in this TLS panel that can cause death within minutes through a primary cardiac mechanism ^[1][2][3]. Hyperuricemia and hyperphosphatemia are serious but act through renal injury, which is a slower process and is still compensated here by adequate urine output. Hypocalcemia is dangerous only when it produces neuromuscular or cardiac manifestations, which are absent. Key point! In TLS, the order of immediate threat is potassium first, then uric acid and phosphate (renal), then calcium only if symptomatic. The management priority mirrors this: cardiac monitoring and urgent potassium-lowering measures precede aggressive hydration, rasburicase for uric acid, and phosphate binders ^[1][4].